人工晶体销售放量对冲集采降价影响，视力保健业务收入占比提升至 30%。 1）人工晶体收入 5.88 亿（+17.66%），销量同比增长 44.93%，"全视"多 焦晶体等高端产品增长迅速但占比较低，受集采影响的人工晶体价格下调较 多。2）"普诺瞳"角膜塑形镜收入 2.36 亿（+8.03%），销量同比增长 2.40%， 公司积极丰富产品布局，推出了多种规格的离焦框架镜和离焦软镜等防控产 品，使得近视防控产品营收实现 20.79%增长。3）隐形眼镜收入 4.26 亿 （+211.84%），销量同比增长 241.11%，公司加大隐形眼镜产线建设和市场 投入，核心子公司天眼收入 1.96 亿，净利润 0.08 亿；优你康收入 1.48 亿， 净利润 0.12 亿；美悦瞳收入 0.86 亿，净利润 0.02 亿。 毛净利率受产品结构变化影响，首款国产眼内镜龙晶于 25 年初获批上市。 2024 年毛利率为 66.23%（-9.78pp），主要受相对低毛利率的隐形眼镜产品 收入占比提升的影响。销售费用率 14.12%（-5.17pp），管理费用率 12.12% （+0.03pp），研发费用率 7.60%（-2.24pp ...

Core Viewpoint - Hainan Haiyao Co., Ltd. is accelerating its transformation into an innovative R&D pharmaceutical manufacturer, focusing on the development of new drugs and leveraging the Hainan Free Trade Port policies to enhance its product pipeline and contribute to public health [2][3][4]. Group 1: Innovation and R&D - The company has made significant progress with two new drugs, Fluorofenidone and Paenangin, marking a shift towards innovative drug development [2]. - Hainan Haiyao is committed to developing strategic emerging industries, establishing platforms for large molecule CDMO and national-level testing, and expanding its pipeline for rare and prevalent diseases [2][4]. - The company has increased its R&D investment and has achieved notable success in the generic drug sector, with 34 specifications of 16 products passing consistency evaluations since 2021 [4]. Group 2: International Collaboration and Product Introduction - Hainan Haiyao is actively introducing high-quality foreign products to enrich its product pipeline and enhance medical service levels, establishing partnerships with international biopharmaceutical companies [3]. - The company is negotiating with several global pharmaceutical giants to select products with advanced technology and significant market potential for introduction into China [3]. Group 3: Talent Development and Research Infrastructure - Hainan Haiyao has recruited over 90 high-level R&D talents from prestigious universities both domestically and internationally, establishing a new drug R&D system that integrates production, learning, and research [3]. - The company has set up specialized teams for overseas product introduction and technical analysis to accelerate the integration of advanced biopharmaceutical products [3].

长江商报奔腾新闻记者张璐 金固股份（002488）(002488.SZ)再获全球龙头车企定点。 5月21日，金固股份公告称，公司收到某全球龙头车企的定点通知书，将为其美国产乘用车开发车轮产 品，项目生命周期10年，预计2026年开始量产，前五年销售金额预计约1.58亿美元。 公告显示，这是金固股份在美国本土获得的第二个乘用车OE项目。此前，公司已进入该客户的全球供 应链体系，且阿凡达低碳车轮产品已获得该客户的国内OE项目定点，并批量供货。本次项目定点代表 了美国本土车企对公司在车轮产品研发设计、技术质量、生产能力的充分认可。 公开资料显示，金固股份成立于1996年，2010年于深交所上市，是一家以汽车车轮的研发、生产、销售 为主营业务的高新技术企业，入选浙江省"专精特新"企业名单，公司于2020年底推出了新型轻量化产品 阿凡达低碳车轮。 尽管整体业绩表现平平，但金固股份的阿凡达低碳车轮产品在2024年表现亮眼。报告期内，该产品销量 显著增长，带动了毛利率的提升。阿凡达低碳车轮作为公司重点发展的创新产品，符合新能源汽车市场 的快速发展趋势，成为公司未来增长的重要引擎 进入2025年第一季度，金固股份实现营收8. ...

SSGJ-707 临床效果获国际认可，财务回报助力公司研发体系升级。SSGJ-707 是三生制药基于CLF2 专 利平台开发的靶向PD-1/VEGF 双特异性抗体，可同时抑制PD-1 和VEGF 双靶点。产品潜力大：1）II 期 临床阶段性分析数据显示，SSGJ-707 在NSCLC 患者的治疗上获得了优异的ORR 和DCR，无论单药还 是与化疗联用，均展示出显著的抗肿瘤活性和良好的安全性，具有best-in-class 的潜力。2）今年4 月获 CDE 突破性治疗药物认定，适应症为一线治疗PD-L1 表达阳性的局部晚期或转移性非小细胞肺癌。此 前，SSGJ-707 已获得FDA 的IND 批准。3）SSGJ-707 用于治疗结直肠癌、妇科肿瘤等领域的临床研究 也在推进中。此次合作证明SSGJ-707优异的临床效果已获得国际顶尖认可，同时验证了公司自主创新 研发体系的国际竞争力，显著提升了公司在肿瘤治疗领域的全球话语权，有力地推进了公司的国际化步 伐。此外，此次合作也将为三生制药带来强劲的财务回报，助力公司研发体系升级，推动公司更好地融 入全球生物医药产业价值链。 机构：国盛证券 研究员：张金洋/胡偌碧/张玉 ...

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. held its 2024 annual performance briefing on May 21, 2025, to discuss financial status, development strategy, and corporate governance with investors [1] Group 1: Industry Performance - In 2024, the pharmaceutical manufacturing industry achieved a total revenue of 25,298.5 billion yuan, with a year-on-year change of 0.0% [2] - The industry's total operating costs were 14,729.6 billion yuan, reflecting a year-on-year increase of 2.0% [2] - The total profit for the industry was 3,420.7 billion yuan, showing a year-on-year decline of 1.1% [2] Group 2: Company Financials - The company reported an annual revenue of 2.16 billion yuan, with an operating profit of 131 million yuan and a net profit attributable to shareholders of 84 million yuan [2] - In Q1 2025, the net profit attributable to shareholders was approximately 23.06 million yuan [2] Group 3: Reasons for Profit Decline - The decline in net profit for 2024 was primarily due to a significant increase in R&D investment, reduced investment income, and rising operating expenses influenced by changes in medical insurance policies and market demand [2][4] Group 4: Future Growth Points - The company plans to enhance new drug research and technological innovation, with R&D investment reaching 277 million yuan in 2024, a year-on-year increase of 95.93% [2] - The company has made breakthroughs in innovative R&D, including the advancement of a new drug LH-1801 into phase III clinical trials and the approval of multiple generic drug production licenses [2][4] Group 5: Market and Investor Relations - The company emphasizes value management and investor relations, maintaining a consistent annual dividend payout ratio of 30% [5] - The company is committed to improving its image and enhancing communication with investors through various initiatives [5] Group 6: Regulatory Issues - The company is addressing a recent antitrust penalty by implementing corrective measures and has submitted an application for an administrative penalty hearing [4][5]

证券研究报告 | 公司点评 gszqdatemark 2025 05 21 年 月 日 三生制药（01530.HK） 授权辉瑞 PD-1/VEGF 双抗，创新管线未来可期 公司发布公告：与辉瑞就 PD-1/VEGF 双抗 SSGJ-707 达成授权协议。 5 月 20 日，公司宣布，公司及附属子公司沈阳三生、三生国健与辉瑞签署 协议，将向辉瑞独家授予公司自主研发的突破性 PD-1/VEGF 双特异性抗 体 SSGJ-707 在全球（不包括中国内地）的开发、生产、商业化权利。公 司及沈阳三生将保留 SSGJ-707 在中国内地的开发、生产、商业化权利， 并基于届时商定的财务条款授予辉瑞对 SSGJ-707 在中国内地开展商业化 的选择权。根据协议，三生制药将获得 12.5 亿美元不可退还且不可抵扣 的首付款，以及最高可达 48 亿美元的开发、监管批准和销售里程碑付款。 公司还将根据授权地区的产品销售额收取两位数百分比的梯度销售分成。 此外，辉瑞将于协议生效日认购三生制药价值 1 亿美元的普通股股份。 SSGJ-707 临床效果获国际认可，财务回报助力公司研发体系升级。SSGJ- 707 是三生制药基于 CLF2 ...

证券研究报告 | 公司点评 gszqdatemark 2025 05 21 年 月 日 三生制药（01530.HK） 授权辉瑞 PD-1/VEGF 双抗，创新管线未来可期 公司发布公告：与辉瑞就 PD-1/VEGF 双抗 SSGJ-707 达成授权协议。 5 月 20 日，公司宣布，公司及附属子公司沈阳三生、三生国健与辉瑞签署 协议，将向辉瑞独家授予公司自主研发的突破性 PD-1/VEGF 双特异性抗 体 SSGJ-707 在全球（不包括中国内地）的开发、生产、商业化权利。公 司及沈阳三生将保留 SSGJ-707 在中国内地的开发、生产、商业化权利， 并基于届时商定的财务条款授予辉瑞对 SSGJ-707 在中国内地开展商业化 的选择权。根据协议，三生制药将获得 12.5 亿美元不可退还且不可抵扣 的首付款，以及最高可达 48 亿美元的开发、监管批准和销售里程碑付款。 公司还将根据授权地区的产品销售额收取两位数百分比的梯度销售分成。 此外，辉瑞将于协议生效日认购三生制药价值 1 亿美元的普通股股份。 SSGJ-707 临床效果获国际认可，财务回报助力公司研发体系升级。SSGJ- 707 是三生制药基于 CLF2 ...

Financial Data and Key Metrics Changes - Sales for Q1 2025 were $1,767 million, up 2% year over year and up 10% quarter over quarter [6] - Consolidated adjusted EBITDA was $359 million, with specialties driven EBITDA of $262 million, up 7% year over year and 4% quarter over quarter [7] - Specialties driven EBITDA margin improved by approximately 70 basis points to 19% compared to the first quarter of last year [7] Business Line Data and Key Metrics Changes - Industrial Products sales were $344 million, up 3% year over year, with EBITDA of $76 million, up 6% [9] - Potash division reported sales of $405 million and EBITDA of $118 million, with average potash price at $300 CIF per ton, down year over year but up $15 per ton from the previous quarter [11] - Phosphate Solutions division had sales of $573 million, up 3%, and EBITDA of $139 million, with an EBITDA margin of 24% [13] - Growing Solutions division sales were $495 million, up 3% year over year, with EBITDA of $47 million, an increase of 12% [16] Market Data and Key Metrics Changes - Inflation rates were stable in the U.S. and EU, while Brazil saw a 30 basis point increase; China experienced a slight negative inflation of 0.1% year over year [20] - Grain price index increased slightly, with corn, wheat, and soybean prices improving; corn saw the largest quarterly gain [23] - Potash prices increased approximately 9% sequentially, while phosphate prices grew by about 4% [24] Company Strategy and Development Direction - The company aims to drive growth in specialty businesses to differentiate from commodity-based peers and maximize potash sales volumes [34] - Innovation remains a key focus, with plans to develop new products and solutions for existing and new clients [36] - The acquisition strategy continues, with recent acquisitions enhancing regional market presence and local production capabilities [37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about improving market prices and stable supply, but cautioned about the impact of fulfilling lower-priced contracts with China and India [49] - The company maintains its 2025 guidance, expecting EBITDA for specialties driven divisions to be between $950 million to $1,150 million [32] - There is an expectation for higher potash prices, but the company has not made guidance concessions for potential tariffs [33] Other Important Information - The company ended the quarter with available resources of approximately $1,500 million and a net debt to adjusted EBITDA ratio of 1.2 times [31] - A recent management change in the Phosphate Solutions division aims to maintain market share and target geographic expansion [15] Q&A Session Summary Question: Insights on potash trade flows and pricing impact - Management noted that Eurasian players have been inconsistent in their production claims, making it difficult to predict market tightness and pricing impacts [48] Question: More details on the mix shift in Brazil and growing solutions - Brazil's B2B and B2C businesses are performing well, with strong specialty growth attributed to previous acquisitions [52]

2024年，是中国医药制造业深度调整的一年，医药行业在集采、医保控费等政策下面临阵痛。在此背景 下，梓橦宫积极推动新品种塞来昔布胶囊、磷酸奥司他韦胶囊等陆续上市销售，同时积极寻找筛选新药 研发项目并立项研发，全力实现公司稳定经营。数据显示，2024年，公司实现营业收入4.16亿元，同比 增长1.87%；实现归属于上市公司股东的净利润8564.39万元。 本报记者蒙婷婷 5月16日，四川梓橦宫药业股份有限公司（以下简称"梓橦宫"）召开2024年年度报告业绩说明会。公司 董事、总经理李云向《证券日报》记者表示："2025年，公司将持续加大创新研发投入，加快产品结构 优化，持续开拓市场，培育新业绩增长点；高速高质量推进公司二期工程建设项目，提升规模化生产能 力；坚持合规发展，提高管理效率；加强人才队伍建设，强化人才梯队建设及后备人才储备，夯实企业 发展基础，为公司发展注入'新力量'。" 作为中华老字号药企，"梓橦宫"品牌已有245年历史，公司主要从事药品研发、生产与营销，现拥有26 项发明专利，99个药品生产批准文号，涵盖片剂、硬胶囊剂、散剂、剂、软膏剂等多种剂型。目前，公 司已经形成以神经系统类、消化系统类药品为 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 华夏时报（www.chinatimes.net.cn）记者 于娜 北京报道 独家中药注射液产品因违规停产后，益佰制药也尝到了业绩对单品依赖的苦果。 益佰制药2024年年报显示，公司营收较上年下降 22.92%，归母净利润更是陷入深谷，亏损达到 3.17 亿元。核心 产品艾迪注射液自2024 年 4 月停产后所引发的连锁反应，成为压垮公司业绩的关键稻草，公司业绩陷入营收下 滑、利润转亏、现金流减少等不利局面。 | 主要会计数据 | 2024年 | 2023年 | | 本期比上年 | 2022年 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 同期增减 | | | | | | 调整后 | 调整前 | (%) | 调整后 | 调整前 | | 营业收入 | 2.174.031, 578. 87 | 2,820,561,015.00 | 2, 820, 561, 015. 00 | -22. 92 | 2.735,262,838.67 | 2.735. 262, 838. 67 | | 扣除与主营业务无 ...